✦ LIBER ✦

PM2 IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN: A PROSPECTIVE ANALYSIS

✍ Scribed by DA Hughes; S Al-Zubiedi; A Hanson; A Jorgensen; M Pirmohamed

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comment on ‘Costs of managing adverse ev

✍ Charbonneau, C; Sandin, R 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

Costs of managing adverse events in the

✍ Mickisch, G; Gore, M; Escudier, B; Procopio, G; Walzer, S; Nuijten, M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 356 KB

Regarding: ‘Costs of managing adverse ev

✍ Porta, C 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

Reply: Costs of managing adverse events

✍ Mickisch, G H J; Escudier, B; Walzer, S; Nuijten, M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 159 KB

PCN40 COST ANALYSIS OF MANAGING ADVERSE

✍ CI Silva; I Monteiro; B Schwander 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Dabigatran versus warfarin under standar

✍ Nshimyumukiza, Léon; Duplantie, Julie; Gagnon, Mathieu; Douville, Xavier; Fourni 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 276 KB